...
首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Design, synthesis and cholinesterase inhibitory properties of new oxazole benzylamine derivatives
【24h】

Design, synthesis and cholinesterase inhibitory properties of new oxazole benzylamine derivatives

机译:新氧化苄胺衍生物的设计,合成和胆碱酯酶抑制性能

获取原文
           

摘要

The enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are primary targets in attenuating the symptoms of neurodegenerative diseases. Their inhibition results in elevated concentrations of the neurotransmitter acetylcholine which supports communication among nerve cells. It was previously shown for trans-4/5-arylethenyloxazole compounds to have moderate AChE and BChE inhibitory properties. A preliminary docking study showed that elongating oxazole molecules and adding a new NH group could make them more prone to bind to the active site of both enzymes. Therefore, new trans-amino-4-/5-arylethenyl-oxazoles were designed and synthesised by the Buchwald-Hartwig amination of a previously synthesised trans-chloro-arylethenyloxazole derivative. Additionally, naphthoxazole benzylamine photoproducts were obtained by efficient photochemical electrocyclization reaction. Novel compounds were tested as inhibitors of both AChE and BChE. All of the compounds exhibited binding preference for BChE over AChE, especially for trans-amino-4-/5-arylethenyl-oxazole derivatives which inhibited BChE potently (ICsub50/sub in μM range) and AChE poorly (ICsub50/sub?100?μM). Therefore, due to the selectivity of all of the tested compounds for binding to BChE, these compounds could be applied for further development of cholinesterase selective inhibitors.HIGHLIGHTSSeries of oxazole benzylamines were designed and synthesisedThe tested compounds showed binding selectivity for BChENaphthoxazoles were more potent AChE inhibitors.
机译:酶乙酰胆碱酯酶(ACHE)和丁酰胆碱酯酶(BCHE)是衰减神经变性疾病症状的主要靶标。它们的抑制结果导致升高的神经递质乙酰胆碱浓度,其支持神经细胞之间的通信。以前所示的反式4 / 5-芳基乙氧基唑化合物具有中等疼痛和BCHE抑制性能。初步对接的研究表明,伸长的恶唑分子和添加新的NH组可以使它们更容易与两种酶的活性位点结合。因此,通过预先合成的反式氯 - 芳基乙烯氧唑衍生物的Buchwald-Hartwig胺化设计和合成了新的反式氨基-4- / 5-芳基乙基 - 恶唑。另外,通过有效的光化学电循环反应获得萘恶唑苄胺光调解物。将新化合物作为疼痛和BCHE的抑制剂进行测试。所有化合物都表现出BCHE对疼痛的结合偏好,特别是对于抑制BCHE的反式氨基-4- / 5-芳基乙基 - 恶唑衍生物(IC 50 INμm范围)和疼痛差(IC 50 ?100?μm)。因此,由于所有测试化合物的选择性与BCHE结合,这些化合物可以应用于进一步发展胆碱酯酶选择性抑制剂。设计并合成了氧唑苄胺的高灯晶体,该化合物显示出BChenaphthoxoOxazoles的结合选择性是更有效的疼痛抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号